Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Status:
Not yet recruiting
Trial end date:
2027-04-14
Target enrollment:
Participant gender:
Summary
The purpose of the study in Part 1 (dose escalation) is to determine the recommended Phase 2
dose(s) (RP2D[s]) and in Part 2 (dose expansion) is to determine the safety of Erdafitinib
Intravesical Delivery System administered at the RP2D(s).